Tularemia Market 2019: Key Players-Glaxo Smithkline, Bayer AG, Ranbaxy Laboratories, Cipla Inc., Zydus Cadila upto 2023

Market Research Future (MRFR) has announced a new release on the Global Tularemia market. The report takes into account the global Tularemia market’s historical growth trajectory and major growth drivers and restraints in order to come up with a reliable projection for the market’s likely growth trajectory over the forecast period from 2018 to 2023.

Market Scenario

Tularemia or rabbit fever or deer fly fever is a rare infectious disease caused by the bacterium Francisella tularensis, which affects skin, eyes, lymph nodes and lungs. Tularemia is transmitted from animals such as rodents, rabbits, and hares to human. It can also affect sheep, birds, dogs, cats, etc. The routes of acquiring infection are direct exposure to the bacteria, airborne infections, insect bites, and bite of an infected animal. Tularemia is highly contagious and had been used as a biological weapon by many countries such as United States of America and Soviet Union. Ulceroglandular tularemia is the most common form of Tularemia. Tularemia symptoms include swollen and painful lymph glands, fever, chills, headache, fatigue, eye swelling, pain and light sensitivity, diarrhea, pneumonia etc. If it left untreated, it will cause serious complications such as enlarged spleen, enlarged liver, infection around the brain and spinal cord, irritation around the heart (pericarditis), bone infection etc. and may lead to the death.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4120

Factors favouring the spread of Tularemia infection are tick bites, exposure to sick or dead animals, especially, wild game. Travel to certain regions such as Arkansas, Missouri and Oklahoma can also cause Tularemia infection because of the concentration of ticks in those areas. Tick bite is the leading cause for an occurrence of large number of cases.Laboratory workers working with tularemia are at risk of airborne infection due to greater chances of exposure to the pathogen. Tularemia infection can also be airborne during gardening, construction or other activities, which may lead to pneumonic tularemia. Tularemia is also contracted by eating undercooked meat of an infected animal or drinking contaminated water. According to Centers for Disease Control and Prevention, overall mortality of Tularemia is less than 2% but ranges up to 24% depending on the strain.

The Global Tularemia market is expected to reach US$ 200 million by 2023, and the market is projected to grow at a CAGR of ~ 3.2 % during the forecast period 2017-2023.

Key Players in the Global Tularemia Market

• Nicholas Piramal,
• Alkem,
• Glaxo Smithkline,
• Bayer AG,
• Ranbaxy Laboratories,
• Cipla Inc.,
• Zydus Cadila,
• Dr. Reddy's Lab,
• Glenmark Pharmaceuticals,
• Lupin Limited,
• pfizer Inc. and others.

Segmentations

The global Tularemia market has been segmented on the basis of types, diagnosis, drugs, and end users.

Based on types, the market has been segmented as the ulceroglandular tularemia, glandular tularemia, oculoglandular tularemia, oropharyngeal tularemia, pneumonic tularemia, and others.

Based on the diagnosis, the market has been segmented as microscopy, immunochemistry, and others.

Based on the drugs, the market has been segmented as streptomycin, gentamicin, doxycycline, ciprofloxacin and others.

Based on the end users, the market has been segmented as hospitals and clinics, academic and research centers, and others.

Regional analysis

The Americas accounts for the significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new technology and drugs in the US drives the global Tularemia market. However the presence and concentration of Tularemia in the US regions, for instance, Arkansas, Missouri, Dakota, Oklahoma, etc. are the leading cause for the dominance of US in the global Tularemia market. Europe is the second largest market in the globe due to a high disposable income and rising awareness about the disease.

Asia Pacific region is expected to grow rapidly and China and India are likely to lead the market due to unmet needs during the forecast period.

Gulf nations such as Saudi Arabia and the UAE drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. However Africa is also a region of high endemic and untreated cases of Tularemia.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/tularemia-market-4120

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.